Islet Sciences elects Dr William Wilkison to board
M2 - Tue Apr 22, 5:52AM CDT
Biopharmaceutical company Islet Sciences (Other OTC:ISLT) disclosed on Monday the addition of Dr William Wilkison to its board of directors.
Islet Sciences, Inc. Appoints William Wilkison, Ph.D. to Board of Directors
GlobeNewswire - Mon Apr 21, 10:01AM CDT
Islet Sciences, Inc. (OTCQB:ISLT) today announced the appointment of Dr. William Wilkison, COO of Islet Sciences, to Islet's Board of Directors.
Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results for SGLT2 Inhibitor Remogliflozin Etabonate
GlobeNewswire - Wed Apr 16, 11:17AM CDT
Islet Sciences, Inc. (OTCQB:ISLT) and BHV Pharma today announced positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics. The primary end point was HbA1c with secondary end points of fasting plasma glucose, serum lipids, body weight, safety and tolerability. Remogliflozin etabonate is a selective SGLT2 inhibitor indicated for type 2 diabetes and NASH. Islet Sciences will present the full results of the two phase 2b clinical studies at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17th.
Islet Sciences to Host Conference Call to Discuss Acquisition of BHV Pharma
Marketwire - Mon Mar 17, 8:30AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced that on Monday, March 17, 2014, the Company will host a conference call to discuss the announced acquisition of BHV Pharma. The call is scheduled to take place at 4:15 p.m. ET.
Islet Sciences appoints Dr. Michael Luther to board
M2 - Mon Mar 17, 7:55AM CDT
US-based biopharmaceutical company Islet Sciences (OTCQB:ISLT) revealed on Friday the addition of Dr. Michael Luther to its board of directors.
Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors
Marketwire - Fri Mar 14, 8:10AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced the appointment of Dr. Michael Luther, Senior Vice President of Discovery and Development at Albany Molecular Research, Inc. to Islet's Board of Directors.
Islet Sciences to buy BHV Pharma, including Phase two SGLT2 inhibitor remogliflozin etabonate for Type 2 diabetes and NASH
M2 - Fri Mar 14, 4:10AM CDT
Biopharmaceutical company Islet Sciences (OTCBB:ISLT) (OTCQB:ISLT) said on Thursday that it has entered into a binding letter of intent to acquire Brighthaven Ventures /BHV Pharma (BHV), including the remogliflozin programme.
Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH
Marketwire - Thu Mar 13, 8:15AM CDT
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that it has signed a binding letter of intent to acquire Brighthaven Ventures, LLC d/b/a BHV Pharma ("BHV"
CORWIL Technology Corporation Completes Asset Purchase Of VIKO Test Labs
PR Newswire - Mon Mar 10, 10:01PM CDT
CORWIL Technology Corporation ("CORWIL"
Islet Sciences Inc names Dr Eric Barnett to board
M2 - Tue Jan 07, 5:47AM CST
Biopharmaceutical company Islet Sciences Inc (OTCBB:ISLT) (OTCQB:ISLT) reported on Monday the election of Dr Eric Barnett to its board of directors.
Dr. Eric Barnett Joins Islet Sciences, Inc. Board of Directors
Marketwire - Mon Jan 06, 11:11AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals LLC, was elected to the Islet Sciences Board of Directors.
Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Marketwire - Thu Dec 12, 7:01AM CST
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)
Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."
Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.
Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy
Business Wire - Mon Jul 08, 8:44AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, will be presenting several scientific presentations at the upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy July 7-11, 2013.
Islet Sciences Chief Scientific Officer Receives $1.27 million in Grant from JDRF to Create Innovative Diabetes Treatments
Business Wire - Thu Jun 27, 3:02PM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, has received $1.27 million in grant funding from the JDRF to develop innovative methods to treat and possibly cure type 1 diabetes. Dr. Jerry Nadler, Dr. Elliot Botvinick and Dr. Paul Johnson, co-investigators in the JDRF grant, are also members of the Company's Scientific Advisory Board.